Drugs / Hyperpolarized Pyruvate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02947373 | Jan 2017 → Apr 2020 | brain neoplasm | University of California, San Francisco | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06391034 | Sep 2024 → Dec 2028 expected | prostate cancer | Robert Bok, MD, PhD | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hyperpolarized pyruvate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06391034 ↗ |
| Modality | Diagnostic / imaging agent | “Hyperpolarized Pyruvate (HP) for metabolic imaging” NCT02947373 ↗ |
| Route | Intravenous | “Given IV” NCT06391034 ↗ |